Strong MedTech investors pair current healthcare investing with clinical, regulatory, reimbursement, and commercialization expertise appropriate to a device's risk class and evidence plan.
Market overview
A useful shortlist must distinguish specialized medical-device funds from broad healthcare investors and show founders what evidence each partnership is built to evaluate.
How this investor list was built
Finta required every entry to pass the same inclusion gates: a current official mandate, current public evidence of an active organization or program, relevant stage or geography fit, and a usable public evidence trail. Entries that passed those gates appear alphabetically. The order is not a performance ranking, recommendation, or guarantee of availability.
This guide compares 11 currently relevant organizations. It was researched on September 2, 2026, after the original publication date shown above. Later evidence is presented as a research update, not as information that was necessarily available on the historical publication date.
Comparison table
| Organization | Why it is included | Public evidence | Public starting point |
|---|---|---|---|
| Arboretum Ventures | Relevant to healthcare companies whose products can improve outcomes or lower system cost, including medical devices. | Arboretum Ventures | Open official starting point |
| Endeavour Vision | Relevant to European and US MedTech companies approaching clinical validation, commercialization, or growth. | Endeavour Vision | Open official starting point |
| ExSight Ventures | Relevant to pre-seed through Series B ophthalmic devices, diagnostics, surgical robotics, imaging, and software where eye-care domain expertise matters. | ExSight Ventures portfolio | Official contact page; no public pitch process stated |
| HealthQuest Capital | Relevant to growth-oriented healthcare innovation across devices, diagnostics, tools, and services. | HealthQuest Capital | Open official starting point |
| Lightstone Ventures | Relevant to novel therapeutics and medical devices where scientific and clinical development expertise is central. | Lightstone Ventures | Open official starting point |
| MedTech Venture Partners | Relevant to early-stage medical-device businesses that need a specialized MedTech investment lens. | MedTech Venture Partners | Open official starting point |
| Santé Ventures | Its published criteria match US-based Seed through Series B healthcare companies with breakthrough MedTech, Biotech, or HealthTech and a defined clinical value case. | Submit a Business Plan | Open official starting point |
| ShangBay Capital | Relevant to medical devices, diagnostics, and related healthcare technology with a commercialization plan. | ShangBay Capital | Open official starting point |
| Sonder Capital | Relevant to healthcare technology and medical-device founders seeking specialist operating and investment support. | Sonder Capital | Open official starting point |
| SV Health Investors Medtech Convergence Fund | Relevant to medical technology at the convergence of devices, diagnostics, data, and care delivery. | Medtech Convergence Fund | Open official starting point |
| Vensana Capital | Relevant to medical-technology companies with a clinically meaningful product and specialist sector needs. | Vensana Capital | Open official starting point |
Investor and capital-source profiles
Arboretum Ventures
Mandate evidence: Arboretum states a healthcare investment focus and publishes device companies in its portfolio.
Current activity evidence: The official site maintains current portfolio and team pages.
Stage or geography evidence: US healthcare venture opportunities, with stage assessed directly.
Sources reviewed September 2, 2026: Arboretum Ventures.
Endeavour Vision
Mandate evidence: Endeavour Vision describes a specialist healthcare and MedTech investment strategy.
Current activity evidence: The current site presents an active portfolio and team.
Stage or geography evidence: Transatlantic healthcare focus, with current stage criteria confirmed directly.
Sources reviewed September 2, 2026: Endeavour Vision.
ExSight Ventures
Mandate evidence: ExSight specializes in early-stage ophthalmic diagnostics and treatment solutions, including medical devices and software.
Current activity evidence: Its official portfolio includes device and diagnostic companies such as ELIOS Vision, Horizon Surgical Systems, Qura, Envision Diagnostics, and LensGen.
Stage or geography evidence: ExSight states that it invests from pre-seed through Series B. The official pages reviewed do not state a standard check size or universal lead policy.
Sources reviewed September 2, 2026: ExSight Ventures approach and thesis and official portfolio.
HealthQuest Capital
Mandate evidence: HealthQuest publishes a healthcare innovation mandate and corresponding portfolio.
Current activity evidence: Its current site lists active portfolio companies and investment team.
Stage or geography evidence: Company stage and geography vary by fund and transaction.
Sources reviewed September 2, 2026: HealthQuest Capital.
Lightstone Ventures
Mandate evidence: Lightstone presents a life-science strategy that includes medical devices.
Current activity evidence: Its current site maintains portfolio and team pages.
Stage or geography evidence: Invests across early company formation and venture rounds, subject to current fund criteria.
Sources reviewed September 2, 2026: Lightstone Ventures.
MedTech Venture Partners
Mandate evidence: The firm's stated focus is medical technology investing.
Current activity evidence: The current site presents its team and portfolio.
Stage or geography evidence: Early-stage MedTech, with exact current criteria confirmed directly.
Sources reviewed September 2, 2026: MedTech Venture Partners.
Santé Ventures
Mandate evidence: Santé states an explicit focus on Biotech, MedTech, and HealthTech.
Current activity evidence: The firm announced Fund V in 2026 and publishes current portfolio activity.
Stage or geography evidence: Official criteria say Seed, Series A, or Series B, usually US headquartered.
Publicly disclosed check information: The official criteria page reported $5M to $8M initially and up to $25M over a partnership as reviewed September 2, 2026; founders should confirm current terms directly.
Sources reviewed September 2, 2026: Submit a Business Plan.
ShangBay Capital
Mandate evidence: ShangBay describes a dedicated healthcare venture strategy with medical-technology investments.
Current activity evidence: The current site publishes portfolio companies and team information.
Stage or geography evidence: Primarily US healthcare opportunities, with round fit confirmed directly.
Sources reviewed September 2, 2026: ShangBay Capital.
Sonder Capital
Mandate evidence: Sonder presents a healthcare technology investment strategy.
Current activity evidence: Its official site lists a current portfolio and team.
Stage or geography evidence: Stage and geography are company-specific and must be confirmed.
Sources reviewed September 2, 2026: Sonder Capital.
SV Health Investors Medtech Convergence Fund
Mandate evidence: SV Health publishes a dedicated Medtech Convergence Fund strategy.
Current activity evidence: The official strategy and portfolio pages remain current and public.
Stage or geography evidence: Healthcare specialist with opportunity-specific stage and geography.
Sources reviewed September 2, 2026: Medtech Convergence Fund.
Vensana Capital
Mandate evidence: Vensana identifies medical technology as its dedicated investment focus.
Current activity evidence: The official site lists an active team and medical-technology portfolio.
Stage or geography evidence: Stage and geography vary by opportunity and require direct confirmation.
Sources reviewed September 2, 2026: Vensana Capital.
How founders can use this list
- Match the investor to device class, clinical evidence, reimbursement, and regulatory path.
- Show how the product improves a measured outcome or reduces a defined cost.
- Confirm capital requirements through validation, approval, manufacturing, and commercialization.
Limits and disclosures
- This list is not medical, regulatory, legal, or investment advice.
- Portfolio evidence does not prove that a fund is currently accepting a similar device or stage.
- Clinical, FDA or other regulatory status, reimbursement, and check information must be confirmed directly.
- Public mandates, application paths, and disclosed terms can change. Reverify every organization before outreach.
- Finta does not provide investment, legal, tax, medical, regulatory, procurement, or export-control advice.
Related investor research
- 20 Top Seed Investors and VC Funds in 2026
- 15 Top Healthtech and Digital Health Investors (2026)
- 20 Top Series A Investors and Lead VC Funds in 2026
- Defense and Dual-Use Investors for Startups (2026)
Turn research into a reviewed fundraising workflow
Use Finta's fundraising workflow to move from investor research to relationship-aware outreach, meeting preparation, and accountable follow-up. A person remains responsible for fit, messaging, introductions, and every external action.